AsiaCOVID-19DiagnosticsNews

Jubilant Life Sciences Announces Launch of ‘JUBI-R’ for Treatment of COVID-19


India : Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company has announce that its subsidiary, Jubilant Generics Limited, has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR4,700 per vial of 100 mg (lyophilized injection). The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. Jubilant’s 24 hour help line will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

“It gives us immense satisfaction to launch ‘JUBI-R’ as this drug has a potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market and in other countries,” stated Mr. Shyam S. Bhartia, Chairman & Managing Director. 

THIS CAN BE YOUR ADVERTISEMENT

In order to increase accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited stated “ The Company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs.

In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease. On July 20, 2020, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir (“JUBI-R”) for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19. ‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close